Mirum Pharmaceuticals
Public biopharma developing therapies for rare liver diseases; maker of FDA-approved LIVMARLI for Alagille syndrome. Founded 2018, HQ Foster City. ~392 staff. Public (NASDAQ: MIRM) since 2019.
Public biopharma developing therapies for rare liver diseases; maker of FDA-approved LIVMARLI for Alagille syndrome. Founded 2018, HQ Foster City. ~392 staff. Public (NASDAQ: MIRM) since 2019.